Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Lim

Showing results (11-20 of 106) with videos related to

Pageof 11
Sort By:
Annals of Internal Medicine|June 1, 2026
In adults with acute VTE, apixaban vs. rivaroxaban reduced clinically relevant bleeding at 3 moSiraj Mithoowani, Wendy Lim,
Current Opinion in Pulmonary Medicine|October 18, 2007
Low molecular weight heparin and bleeding in patients with chronic renal failureMark Crowther, Wendy Lim
Annals of Internal Medicine|June 6, 2022
Adults with first-time nephrotic syndrome had increased risk for thromboembolic events, higher near time of diagnosisSiraj Mithoowani, Wendy Lim
Hematology. American Society of Hematology. Education Program|December 17, 2009
ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?Ara Metjian, Wendy Lim
Critical Care (London, England)|August 2, 2006
Measuring the anticoagulant effect of low molecular weight heparins in the critically illMark Crowther, Wendy Lim
Nature Clinical Practice. Cardiovascular Medicine|November 14, 2007
Re-examining aggressive anticoagulant therapy: the case of acute coronary syndromesMark Crowther, Wendy Lim
Journal of General Internal Medicine|December 15, 2015
Use of Low Molecular Weight Heparins in Patients with Renal Failure; Time to Re-evaluate Our PreconceptionsMark Crowther, Wendy Lim
Current Opinion in Hematology|October 16, 2007
Antiphospholipid antibiodies: a critical review of the literatureWendy Lim, Mark A Crowther
Hematology. American Society of Hematology. Education Program|December 10, 2013
Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism?David A Garcia, Wendy Lim
Transfusion|May 30, 2008
The use and abuse of surrogate endpoints in clinical research in transfusion medicineDonald M Arnold, Wendy Lim
Pageof 11

Showing results (11-20 of 106) with videos related to

Sort By:
Pageof 11
Annals of Internal Medicine|June 1, 2026
In adults with acute VTE, apixaban vs. rivaroxaban reduced clinically relevant bleeding at 3 moSiraj Mithoowani, Wendy Lim,
Current Opinion in Pulmonary Medicine|October 18, 2007
Low molecular weight heparin and bleeding in patients with chronic renal failureMark Crowther, Wendy Lim
Annals of Internal Medicine|June 6, 2022
Adults with first-time nephrotic syndrome had increased risk for thromboembolic events, higher near time of diagnosisSiraj Mithoowani, Wendy Lim
Hematology. American Society of Hematology. Education Program|December 17, 2009
ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?Ara Metjian, Wendy Lim
Critical Care (London, England)|August 2, 2006
Measuring the anticoagulant effect of low molecular weight heparins in the critically illMark Crowther, Wendy Lim
Nature Clinical Practice. Cardiovascular Medicine|November 14, 2007
Re-examining aggressive anticoagulant therapy: the case of acute coronary syndromesMark Crowther, Wendy Lim
Journal of General Internal Medicine|December 15, 2015
Use of Low Molecular Weight Heparins in Patients with Renal Failure; Time to Re-evaluate Our PreconceptionsMark Crowther, Wendy Lim
Current Opinion in Hematology|October 16, 2007
Antiphospholipid antibiodies: a critical review of the literatureWendy Lim, Mark A Crowther
Hematology. American Society of Hematology. Education Program|December 10, 2013
Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism?David A Garcia, Wendy Lim
Transfusion|May 30, 2008
The use and abuse of surrogate endpoints in clinical research in transfusion medicineDonald M Arnold, Wendy Lim
Pageof 11